AMNEAL PHARMACEUTICALS, INC. (AMRX) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $5.96M; Long-term Debt, Excluding Current MaturitiesUSD $2.56B; Long-term DebtUSD $2.57B; Long-term Debt, GrossUSD $2.68B.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $6.20M; Long-term Debt, Excluding Current MaturitiesUSD $2.57B; Long-term DebtUSD $2.57B; Long-term Debt, GrossUSD $2.69B.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $6.76M; Long-term Debt, Excluding Current MaturitiesUSD $2.57B; Long-term DebtUSD $2.57B; Long-term Debt, GrossUSD $2.69B.
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $7.20M; Long-term Debt, Excluding Current MaturitiesUSD $2.57B; Long-term DebtUSD $2.57B; Long-term Debt, GrossUSD $2.70B.
AMNEAL PHARMACEUTICALS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-term Debt, Gross USD | Long-term Debt and Lease Obligation, Current USD | Long-term Debt and Lease Obligation USD | Long-term Debt and Lease Obligation, Including Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Line of Credit Facility, Remaining Borrowing Capacity USD | Notes Payable, Related Parties, Current USD | Notes Payable, Related Parties, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.96M | $2.56B | $2.57B | $2.68B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $6.20M | $2.57B | $2.57B | $2.69B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $6.76M | $2.57B | $2.57B | $2.69B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $7.20M | $2.57B | $2.57B | $2.70B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $31.18M | $2.15B | $2.18B | $2.26B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $31.79M | $2.15B | $2.19B | $2.28B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $224.21M | $2.16B | $2.39B | $2.48B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $224.69M | $2.17B | $2.39B | $2.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $225.16M | $2.18B | $2.40B | $2.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $33.66M | $2.38B | $2.41B | $2.53B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $34.12M | $2.39B | $2.42B | $2.54B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $30.53M | $2.54B | $2.57B | $2.58B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $30.41M | $2.55B | $2.58B | $2.59B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $245.90M | (m) | (m) |
| 2023-03-31 | $29.96M | $2.56B | $2.59B | $2.60B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $245.90M | (m) | $40.13M |
| 2022-12-31 | $29.96M | $2.59B | $2.62B | $2.64B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $39.71M |
| 2022-09-30 | $29.94M | $2.61B | $2.64B | $2.65B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $39.28M |
| 2022-06-30 | $29.92M | $2.62B | $2.65B | $2.67B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $38.86M |
| 2022-03-31 | $30.52M | $2.67B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $38.44M |
| 2021-12-31 | $30.61M | $2.68B | $2.71B | $2.73B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $38.04M |
| 2021-09-30 | $30.47M | $2.69B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $37.63M |
| 2021-06-30 | $30.46M | $2.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $37.22M |
| 2021-03-31 | $29.82M | $2.73B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $36.83M |
| 2020-12-31 | $44.23M | $2.74B | $2.78B | $2.81B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $36.44M |
| 2020-12-31 | (m) | (m) | (m) | (m) | $44.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $29.78M | $2.76B | $2.79B | $2.81B | $29.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $36.05M |
| 2020-06-30 | $29.76M | $2.76B | $2.79B | $2.82B | $29.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $35.66M |
| 2020-03-31 | $29.74M | $2.77B | $2.80B | $2.83B | $29.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $35.28M |
| 2020-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $9.00M | $9.00M | $9.00M | $9.00M | (m) | (m) | (m) |
| 2019-12-31 | $21.48M | $2.61B | $2.63B | $2.66B | $21.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 |
| 2019-09-30 | (m) | $2.61B | (m) | (m) | $21.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.62B | (m) | (m) | $21.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $2.63B | (m) | (m) | $21.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $21.45M | $2.63B | $2.65B | $2.69B | $21.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | $121.69M | $2.68B | $2.80B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $78.13M | (m) |
| 2018-06-30 | (m) | $2.64B | $2.66B | $2.70B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $77.55M | (m) |
| 2018-05-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $27.00M | $27.00M | $27.00M | $27.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-05-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $27.00M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $89.17M | $1.36B | $1.44B | $1.45B | $89.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $1.40B | $1.48B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |